Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 26, 2025Frontiers in ImmunologyOpen Access

Inflammation-associated drug resistance and tumor growth in TNBC

View Full Paper
Ask AI
Bookmark
Share

Authors

AHArij Fouzat HassanHKHadeel KheraldineLALama Abujamous

Discussion

Loading...

Member takes

Overview

Review examines cytokines and inflammation's role in tumor growth in TNBC, highlighting therapeutic resistance challenges.

Key Points

  • Inflammation contributes to therapeutic resistance in triple-negative breast cancer, leading to poor treatment outcomes.
  • Key cytokines like TNF-α and IL-6 influence the tumor microenvironment, promoting tumor growth and metastasis.
  • Analysis of preclinical and clinical studies identifies potential therapies targeting inflammation to improve TNBC treatment.
  • Understanding the role of inflammation in TNBC highlights the need for innovative approaches in managing this aggressive cancer.

Cite This Study

Hassan et al. (2025) studied this question.

synapsesocial.com/papers/68af7c8d7567bf4f94ff3d80https://doi.org/10.3389/fimmu.2025.1623137
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunotherapy resistance in triple-negative breast cancer: Molecular mechanisms, tumor microenvironment, and therapeutic implications2025 · 27 citations
  2. 2The Role of Tumor Microenvironment in Triple-Negative Breast Cancer and Its Therapeutic Targeting2025
  3. 3Cytokine Networks in Triple-Negative Breast Cancer: Mechanisms, Therapeutic Targets, and Emerging Strategies2025
  4. 4Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation2025 · 5 citations
  5. 5Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies2025 · 5 citations